Genentech announced that the company is working with the U.S. FDA to initiate a randomized, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced Research and Development Authority, a part of the U.S. HHS Office of the Assistant Secretary for Preparedness and Response, to evaluate the safety and efficacy of Actemra® plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia compared to placebo plus standard of care.
March 19, 2020
· 6 min read